Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death
Noel G. Carlson(University of Utah), John Rose(VA Salt Lake City Healthcare System)
Cited by 40
Related Papers
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
|The Lancet Neurology|2010|300
Daclizumab phase II trial in relapsing and remitting multiple sclerosis
|Neurology|2007|161
Open-label, add-on trial of cetirizine for neuromyelitis optica
|Neurology Neuroimmunology & Neuroinflammation|2018|26